Skip to main content
. 2021 May 5;25(11):5082–5098. doi: 10.1111/jcmm.16491

FIGURE 7.

FIGURE 7

miR‐454 inhibits cardiomyocyte apoptosis and injury by activating the cAMP pathway through NEDD4‐2/TrkA axis. H9c2 cells were treated with mimic NC + DMSO, miR‐454 mimic + DMSO or miR‐454 mimic + H‐89 for 48 h. A, The expression of miR‐454 in H9c2 cells determined by RT‐qPCR. B, The mRNA expression of NEDD4‐2 in H9c2 cells determined by RT‐qPCR; */# P < .05. C, The protein expression of NEDD4‐2 and TrkA and the extents of PKA and CREB phosphorylation in H9c2 cells determined by Western blot assay; */# P < .05. D, ROS levels in H9c2 cells; */# P < .05. E, The activities of SOD in H9c2 cells examined by ELISA; */# P < .05. F, The activities of CAT in H9c2 cells measured by ELISA; */# P < .05. G, The survival rates of H9c2 cells examined by MTT assay; */# P < .05. H, The apoptotic rates of H9c2 cells as examined by flow cytometry; */# P < .05. I, The protein expression of Bax, cleaved caspase‐3 and Bcl‐2 in H9c2 cells determined by Western blot assay; */# P < .05. Measurement data are displayed as mean ± standard deviation. One‐way ANOVA was performed for comparison of data among multiple groups. Each cell experiment was repeated three times